Objective To investigate expression of E-cadherin (E-cad) and ?-catenin (?-Cat) in pancreatic carcinoma and its relationship with the biological behavior. Methods Immunohistochemistry staining (PicTure TM two steps method) was used to detect E-cad and ?-Cat expression in 47 specimens of paraffin-embeded pancreatic carcinoma and 17 normal pancreas around tumors. Results E-cad and ?-Cat were expressed by normal ductal and acinar cells with typical membranous staining at the intercellular junctions. 17 normal specimens of pancreas strongly expressed E-cad and ?-Cat. The loss and reduction rate of E-cad expression in pancreatic carcinoma was 53.2%(25/47). The significant relationship was observed between low E-cad expression and differentiation,high hyperplastic grade and metastasis (P0.05). There was a positive relationship between the expression of E-cad and ?-Cat in the same specimen (r=0.88,P

0.05).Conclusion:The lymphoid tissues can not only express the ACTH-R?5-HT_ 1A-R protein but also synthesize their mRNA.ACTH and 5-HT can regulate the functions of the immune system through their receptors on the membrane of the immunocytes.

Objective:To investigate the expression of MACC1 in Klatskin tumor and the relationship between the clinicopathological features and prognosis and the expression of MACC1.Methods:Immunohistochemistry staining was employed to assess the expression of MACC1 protein in Klatskin tumor tissues and matched adjacent non-tumor bile duct tissues.Quantitative real-time PCR was performed to examine MACC1 mRNA expression in Klatskin tumor tissues and the adjacent non-tumor bile duct tissues and normal bile duct tissues.The correlation between MACC1 expression and the clinicopathological features and prognosis was analyzed.Results:The positive rate of MACC1 in Klatskin tumor tissues was significantly higher than that in matched adjacent non-tumor bile duct tissues(P＜0.05).MACC1 mRNA expression in carcinoma tissues was significantly higher than that in the non-tumor bile duct tissues and normal bile duct tissues(P＜0.05).MACC1 expression in Klatskin tumor tissues was related to tumor size,recurrence and lymphatic metastasis(P＜0.05).Survival analysis indicated that the 1-year,3-year,5-year survival rate were with significantly differences between the two groups (P＜0.05).Conclusion:MACC1 expression was significantly higher in Klatskin tumor and it was related to the tumor size,recurrence and lymphatic metastasis.It would affect the prognosis of patients.

Objective　 To investigate gene rearrangement and p53 expression i n defining the nature of angioimmunoblastic lymphadenopathy. Methods　 DNA was ext racted from paraffin-embedded tissue blocks of 44 angioimmunoblastic lymphaden o pathy (AIL) patients and analyzed with polymerase chain reaction (PCR) for IgH and TCRγ gene rearrangement. Immunohistochemistry staining was used to detect p53 protein expression. Thirty-five cases were followed-up. Results　 12 out of 44 cases(27.3%) showed TCRγ gene rearr angement and 2 (4.5%) showed IgH gene rearrangement. Rearrangement of both IgH a nd TCRγ genes were detected in 2 cases(4.5%). 14 cases (31.8%) showed p53 posit i ve expression, among which 12 showed positive rearrangement and 2 showed negative (P<0.01). Eight out of 11 patients of p os itive gene rearrangement died in one year, while only 3 patients were still aliv e at the eighteenth month of follow-up, three of 24 patients of negative gene r earrangement were found dead at the time of the one year follow-up, while the r est 21 patients were alive and the longest survival time was 96 months. Conclusions　 Gene rearrangement can define th e pathological nature of AIL. The expression of p53 is highly related to gene r earrangement, and thus an important immunological marker in research on AIL.

The outbreak and spread of coronavirus disease 2019 (COVID-19) highlighted the importance and urgency of the research and development of therapeutic drugs. Very early into the COVID-19 pandemic, China has begun developing drugs, with some notable progress. Herein, we summarizes the anti-COVID-19 drugs and promising drug candidates originally developed and researched in China. Furthermore, we discussed the developmental prospects, mechanisms of action, and advantages and disadvantages of the anti-COVID-19 drugs in development, with the aim to contribute to the rational use of drugs in COVID-19 treatment and more effective development of new drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the variants. Neutralizing antibody is an effective approach to overcome COVID-19. However, drug resistance induced by rapid virus mutation will likely to challenge neutralizing antibodies. Taking into account current epidemic trends, small molecule drugs have a crucial role in fighting COVID-19 due to their significant advantage of convenient administration and affordable and broad-spectrum. Traditional Chinese medicines, including natural products and traditional Chinese medicine prescriptions, contribute to the treatment of COVID-19 due to their unique mechanism of action. Currently, the research and development of Chinese anti-COVID-19 drugs have led to some promising achievements, thus prompting us to expect even more rapidly available solutions.